$FMS (+6.4% pre) Fresenius Medical Care starts 2025 with strong organic revenue and income growth https://t.co/4X2SHIgxj1
$BVS Bioventus Q1 Adj. EPS $0.08 Beats $0.02 Estimate Sales $123.88M Beat $122.70M Estimate
$FMS Fresenius Medical Care Q1 Adj. EPS $0.44 Beats $0.38 Estimate Sales $5.13B Beat $4.74B Estimate
Several companies reported their first and second-quarter earnings results, surpassing analyst estimates. Zimmer Biomet Holdings (ZBH) posted first-quarter adjusted earnings per share (EPS) of $1.81, beating the estimated $1.77, with sales of $1.91 billion, slightly above the $1.90 billion forecast. Tyson Foods Inc. (TSN) reported second-quarter adjusted EPS of $0.92, exceeding the $0.82 estimate, while revenue was $13.07 billion, slightly missing the $13.14 billion estimate. Tyson Foods anticipates full-year 2025 adjusted operating income between $1.9 billion and $2.3 billion and expects sales growth of flat to 1% year-over-year. Zoetis (ZTS) delivered first-quarter adjusted EPS of $1.48, beating the $1.39 estimate, with sales of $2.22 billion, above the $2.19 billion forecast. Fresenius Medical Care (FMS) reported first-quarter adjusted EPS of $0.44, surpassing the $0.38 estimate, and sales of $5.13 billion, exceeding the $4.74 billion estimate. The company started 2025 with strong organic revenue and income growth, which contributed to a 3% increase in its stock price. Bioventus (BVS) posted first-quarter adjusted EPS of $0.08, beating the $0.02 estimate, with sales of $123.88 million, slightly above the $122.70 million forecast.
